Deepening the strategic partnership between Russia and China in the field of pharmaceutical research is becoming high priority for both countries. This is not only important for government interests but also represents a huge prospect for companies in the field of pharmaceuticals and biotechnology, contract research organizations (CROs) as well as academic institutions, such as the Russian Sirius University of Science and Technology. Roman Ivanov, Director of the Scientific Center of Translational Medicine of the Sirius University, uncovers the key directions of mutual interest for Chinese and Russian companies within the pharmaceutical industry of both countries. Subscribe to our channel to keep up to date with the main trends in clinical research in Russia. Our Website: Our Experience: Media Center: ✉ We will be waiting for your requests by e-mail: info@
Hide player controls
Hide resume playing